NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $5.50 -0.18 (-3.17%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precision BioSciences Stock (NASDAQ:DTIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$5.41▼$5.6950-Day Range$4.23▼$5.9152-Week Range$3.61▼$13.44Volume85,367 shsAverage Volume178,793 shsMarket Capitalization$58.03 millionP/E Ratio91.68Dividend YieldN/APrice Target$37.67Consensus RatingBuy Company OverviewPrecision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More… Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreDTIL MarketRank™: Precision BioSciences scored higher than 78% of companies evaluated by MarketBeat, and ranked 95th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is 91.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is 91.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.24.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.82% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently increased by 21.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted21.82% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently increased by 21.74%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.48 News SentimentPrecision BioSciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Precision BioSciences this week, compared to 2 articles on an average week.Search Interest4 people have searched for DTIL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have bought 181.64% more of their company's stock than they have sold. Specifically, they have bought $17,225.00 in company stock and sold $6,116.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Stock News HeadlinesInsider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,250 Shares of StockMarch 28, 2025 | insidertrades.comPrecision BioSciences stock rises following FDA Fast Track designationApril 15, 2025 | in.investing.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 25, 2025 | Paradigm Press (Ad)Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BApril 15, 2025 | businesswire.comPrecision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | businesswire.comAssessing Precision BioSciences: Insights From 4 Financial AnalystsMarch 21, 2025 | nasdaq.comPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025March 21, 2025 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $3.81 at the beginning of 2025. Since then, DTIL stock has increased by 44.4% and is now trading at $5.50. View the best growth stocks for 2025 here. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) announced its quarterly earnings results on Wednesday, March, 26th. The company reported ($3.20) earnings per share for the quarter, missing analysts' consensus estimates of ($2.09) by $1.11. The firm had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.28 million. Precision BioSciences had a negative trailing twelve-month return on equity of 23.69% and a net margin of 11.48%. When did Precision BioSciences' stock split? Precision BioSciences shares reverse split on Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia Oyj (NOK) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings3/26/2025Today4/25/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$37.67 High Stock Price Target$60.00 Low Stock Price Target$19.00 Potential Upside/Downside+584.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.90 Trailing P/E Ratio91.68 Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,320,000.00 Net Margins11.48% Pretax Margin15.28% Return on Equity-23.69% Return on Assets-6.98% Debt Debt-to-Equity Ratio0.34 Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$68.70 million Price / Sales0.84 Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book1.21Miscellaneous Outstanding Shares10,550,000Free Float7,364,000Market Cap$58.03 million OptionableNo Data Beta1.59 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:DTIL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.